JP2010510801A - 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物 - Google Patents

生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物 Download PDF

Info

Publication number
JP2010510801A
JP2010510801A JP2009538805A JP2009538805A JP2010510801A JP 2010510801 A JP2010510801 A JP 2010510801A JP 2009538805 A JP2009538805 A JP 2009538805A JP 2009538805 A JP2009538805 A JP 2009538805A JP 2010510801 A JP2010510801 A JP 2010510801A
Authority
JP
Japan
Prior art keywords
fgf receptor
fusion
cancer
modified soluble
sfgfr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009538805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510801A5 (OSRAM
Inventor
ネスビツト，マーク
カムロン，ベアトリス
ブランシユ，フランシス
ソルデロ，シルビ
ニコラジ，セリーヌ
トロンブ，マルク
Original Assignee
サントリオン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010510801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サントリオン filed Critical サントリオン
Publication of JP2010510801A publication Critical patent/JP2010510801A/ja
Publication of JP2010510801A5 publication Critical patent/JP2010510801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009538805A 2006-11-28 2007-11-28 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物 Pending JP2010510801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (2)

Publication Number Publication Date
JP2010510801A true JP2010510801A (ja) 2010-04-08
JP2010510801A5 JP2010510801A5 (OSRAM) 2010-09-09

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538805A Pending JP2010510801A (ja) 2006-11-28 2007-11-28 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物

Country Status (33)

Country Link
US (3) US8119770B2 (OSRAM)
EP (1) EP2092069B2 (OSRAM)
JP (1) JP2010510801A (OSRAM)
KR (1) KR20090102769A (OSRAM)
AR (1) AR063975A1 (OSRAM)
AT (1) ATE509106T1 (OSRAM)
AU (1) AU2007326985C1 (OSRAM)
BR (1) BRPI0719290A2 (OSRAM)
CA (1) CA2668932A1 (OSRAM)
CL (1) CL2007003411A1 (OSRAM)
CO (1) CO6190564A2 (OSRAM)
CR (1) CR10777A (OSRAM)
CY (1) CY1112435T1 (OSRAM)
DK (1) DK2092069T3 (OSRAM)
EA (1) EA018700B1 (OSRAM)
EC (1) ECSP099361A (OSRAM)
GT (1) GT200900137A (OSRAM)
HR (1) HRP20110503T1 (OSRAM)
IL (1) IL198480A0 (OSRAM)
MA (1) MA31143B1 (OSRAM)
MX (1) MX2009005692A (OSRAM)
MY (1) MY145914A (OSRAM)
NI (1) NI200900097A (OSRAM)
NO (1) NO20092414L (OSRAM)
PE (1) PE20081250A1 (OSRAM)
PL (1) PL2092069T3 (OSRAM)
PT (1) PT2092069E (OSRAM)
RS (1) RS51911B (OSRAM)
SI (1) SI2092069T1 (OSRAM)
SV (1) SV2009003272A (OSRAM)
TN (1) TN2009000184A1 (OSRAM)
TW (1) TW200839012A (OSRAM)
WO (1) WO2008065543A2 (OSRAM)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508759A (ja) * 2011-02-24 2014-04-10 サノフイ シアリル化抗体の生産の方法
JP2016512426A (ja) * 2013-03-11 2016-04-28 ジェンザイム・コーポレーション 糖類工学による部位特異的抗体−薬物コンジュゲーション
JP2016524611A (ja) * 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク がんを治療する方法
JP2020504075A (ja) * 2017-11-30 2020-02-06 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
JP2021511297A (ja) * 2018-01-26 2021-05-06 ジェネンテック， インコーポレイテッド ＩＬ−２２ Ｆｃ融合タンパク質及び使用方法
US11186638B2 (en) 2011-09-12 2021-11-30 Genzyme Corporation Anti-αβTCR antibody
US11697690B2 (en) 2014-03-19 2023-07-11 Genzyme Corporation Site-specific glycoengineering of targeting moieties
US12365734B2 (en) 2019-04-03 2025-07-22 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation
US12503498B2 (en) 2012-09-12 2025-12-23 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2520654T3 (pl) 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
PL2498799T3 (pl) 2009-11-13 2017-03-31 Five Prime Therapeutics, Inc. Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
CN107050426A (zh) * 2010-11-15 2017-08-18 戊瑞治疗有限公司 Fgfr1胞外域组合疗法
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2655408B1 (en) 2010-12-23 2016-07-06 Sanofi Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10016484B2 (en) * 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
CA2896951A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
US12448415B2 (en) * 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503604A (ja) * 1989-02-28 1992-07-02 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Ｎ―連結グリコシル化部位含有ｉｌ―２アナローグ
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
JP2004504016A (ja) * 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
WO2007010401A2 (en) * 2005-07-20 2007-01-25 Cytheris Glycosylated il-7, preparation and uses
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
WO1991017183A1 (en) * 1990-04-27 1991-11-14 Takeda Chemical Industries, Ltd. Proteins with fibroblast growth factor receptor activity
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU662107B2 (en) 1990-07-06 1995-08-24 Aventis Pharmaceuticals Inc. Fibroblast growth factor receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
EP1331266B1 (en) * 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
JPWO2003085118A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
KR100980065B1 (ko) * 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
JP2007525187A (ja) 2003-05-16 2007-09-06 レセプター・バイオロジクス・インコーポレイテッド イントロン融合タンパク質、ならびにその同定方法および使用方法
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503604A (ja) * 1989-02-28 1992-07-02 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー Ｎ―連結グリコシル化部位含有ｉｌ―２アナローグ
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
JP2004504016A (ja) * 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
WO2007010401A2 (en) * 2005-07-20 2007-01-25 Cytheris Glycosylated il-7, preparation and uses
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508759A (ja) * 2011-02-24 2014-04-10 サノフイ シアリル化抗体の生産の方法
US11186638B2 (en) 2011-09-12 2021-11-30 Genzyme Corporation Anti-αβTCR antibody
US12503498B2 (en) 2012-09-12 2025-12-23 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
JP2016512426A (ja) * 2013-03-11 2016-04-28 ジェンザイム・コーポレーション 糖類工学による部位特異的抗体−薬物コンジュゲーション
US12110338B2 (en) 2013-03-11 2024-10-08 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
US11807690B2 (en) 2013-03-11 2023-11-07 Genzyme Corporation Hyperglycosylated binding polypeptides
JP2016524611A (ja) * 2013-05-23 2016-08-18 ファイヴ プライム セラピューティクス インク がんを治療する方法
JP2019023193A (ja) * 2013-05-23 2019-02-14 ファイヴ プライム セラピューティクス インク がんを治療する方法
US11697690B2 (en) 2014-03-19 2023-07-11 Genzyme Corporation Site-specific glycoengineering of targeting moieties
JP2023068027A (ja) * 2017-11-30 2023-05-16 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ－１及びｐｄ－ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
JP2022023168A (ja) * 2017-11-30 2022-02-07 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ－１及びｐｄ－ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
US11919938B2 (en) 2017-11-30 2024-03-05 Grifols Diagnostic Solutions Inc. Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
JP2020504075A (ja) * 2017-11-30 2020-02-06 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 免疫チェックポイント阻害剤ｐｄ−１及びｐｄ−ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
JP2021511297A (ja) * 2018-01-26 2021-05-06 ジェネンテック， インコーポレイテッド ＩＬ−２２ Ｆｃ融合タンパク質及び使用方法
US12365734B2 (en) 2019-04-03 2025-07-22 Genzyme Corporation Anti-alpha beta TCR binding polypeptides with reduced fragmentation

Also Published As

Publication number Publication date
PE20081250A1 (es) 2008-10-07
AU2007326985A1 (en) 2008-06-05
IL198480A0 (en) 2011-08-01
AR063975A1 (es) 2009-03-04
EP2092069B2 (en) 2013-12-18
US8119770B2 (en) 2012-02-21
GT200900137A (es) 2011-09-02
PT2092069E (pt) 2011-07-29
US8481487B2 (en) 2013-07-09
MA31143B1 (fr) 2010-02-01
ECSP099361A (es) 2009-06-30
DK2092069T3 (da) 2011-08-29
CY1112435T1 (el) 2015-12-09
SV2009003272A (es) 2010-02-05
NI200900097A (es) 2010-01-26
CR10777A (es) 2009-07-23
HRP20110503T1 (hr) 2011-08-31
EP2092069A2 (en) 2009-08-26
SI2092069T1 (sl) 2011-09-30
EP2092069B1 (en) 2011-05-11
AU2007326985B2 (en) 2013-08-15
EA200970515A1 (ru) 2009-12-30
MX2009005692A (es) 2009-10-12
ATE509106T1 (de) 2011-05-15
RS51911B (sr) 2012-02-29
PL2092069T3 (pl) 2011-10-31
CA2668932A1 (en) 2008-06-05
CL2007003411A1 (es) 2008-07-04
MY145914A (en) 2012-05-15
AU2007326985C1 (en) 2014-02-20
TW200839012A (en) 2008-10-01
BRPI0719290A2 (pt) 2014-02-25
EA018700B1 (ru) 2013-10-30
WO2008065543A2 (en) 2008-06-05
US20100061979A1 (en) 2010-03-11
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
KR20090102769A (ko) 2009-09-30
NO20092414L (no) 2009-08-21
CO6190564A2 (es) 2010-08-19
WO2008065543A3 (en) 2008-08-14
US20120195851A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
US8481487B2 (en) Modified soluble FGF receptor Fc fusions method
US20220193199A1 (en) Il-15 and il-15ralpha sushi domain based modulokines
US10221246B2 (en) Pan-HER antibody composition
EP2635604B1 (en) Pan-her antibody composition
CN112585161A (zh) 白介素15融合蛋白及其组合物和治疗方法
JP2019194270A (ja) Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用
TW202003561A (zh) 使用靶向4-1bb (cd137)之促效劑的組合療法
CN107446045A (zh) 一种抗her2的抗体、其药物组合物及用途
KR20240099287A (ko) 이종이량체 Fc 시토카인 및 그의 용도
ES2366160T3 (es) Fusiones de fc con receptor para fgf soluble modificadas con actividad biológica mejorada.
HK1139177A (en) Modified soluble fgf receptor fc fusions with improved biological activity
HK40102087A (en) Il-15 and il-15ralpha sushi domain based on modulokines
CN116948012A (zh) 增强细胞功能的cd16抗剪切突变体
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20101227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130402

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20130403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401